Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta DrugsNSE:BETA -1.71%90 EV-to-EBIT is 34.27 as of Aug. 16, 2026, which is 4% above its 10-year median of 32.86. GuruFocus rates NSE:BETA with a GF Score™ of 90/100 and a GF Value™ of ₹2,689.85 (Fairly Valued). The stock has 6 warning signs investors should review. Among 684 Drug Manufacturers companies, Beta Drugs ranks worse than 77.19% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Beta Drugs's Enterprise Value for the quarter that ended in Jun. 2026 was ₹23,357 Mil.
Beta Drugs's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹753 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs EV-to-EBIT Related Terms
Beta Drugs EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Beta Drugs's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Beta Drugs's EV-to-EBIT falls into.
Beta Drugs's current Enterprise Value is ₹25,823 Mil.
Beta Drugs's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹753 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a EV-to-EBIT of 34.27 as of Aug. 16, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Beta Drugs and its competitors. This is near median its historical median of 32.86. Over the past decade, Beta Drugs' EV-to-EBIT has ranged from 11.63 to 135.94. According to the industry distribution chart, Beta Drugs ranks #528 out of 684 companies in the Drug Manufacturers industry, placing it in the top 77.2%.
Is Beta Drugs' EV-to-EBIT too high?
Beta Drugs' current EV-to-EBIT of 34.27 is near median its 10-year median of 32.86. Over the past 10 years, this metric has ranged from a low of 11.63 to a high of 135.94. The Drug Manufacturers industry median EV-to-EBIT is 15.99. Beta Drugs' value of 34.27 is 114.3% above this industry median. Based on the distribution chart, Beta Drugs ranks #528 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beta Drugs has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #528 out of 684 companies for EV-to-EBIT. This places Beta Drugs in the lower half of its industry. The industry median EV-to-EBIT is 15.99. Beta Drugs' value of 34.27 is 114.3% above this benchmark. Historically, Beta Drugs' own EV-to-EBIT has ranged from 11.63 to 135.94 over the past decade. While the company's 10-year median is 32.86 vs. the industry median of 15.99, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current EV-to-EBIT of 34.27 is 114.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current EV-to-EBIT is 34.27, which is near median its own 10-year median of 32.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,689.85, compared to a current price of ₹2,550.70 — trading 5.2% below its estimated fair value. The current EV-to-EBIT is 34.27, which is near median its 10-year median of 32.86 and 114.3% above the Drug Manufacturers industry median of 15.99. Beta Drugs' overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current EV-to-EBIT is 34.27 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be undervalued.
The current stock price of ₹2,550.70 is trading 5.2% below its estimated GF Value™ of ₹2,689.85.
GuruFocus considers Beta Drugs to be Fairly Valued.
Key valuation signals for NSE:BETA:
EV-to-EBIT: 34.27 (near median its 10-year median of 32.86)
GF Value™: ₹2,689.85 vs. price of ₹2,550.70 (5.2% below fair value)
Industry Position: 114.3% above the Drug Manufacturers median (#528 of 684)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
90GF Score
Get the complete analysis for NSE:BETA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
